Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Hisun to collaborate in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China.

The companies have signed a memorandum of understanding on their intention to establish a joint venture with a focus on research, development and commercialisation of off-patent medicines to help build the presence of both firms in the country.

Both parties can contribute existing products and assets to provide a platform for the collaboration.

The move follows a similar agreement Pfizer signed with Chinese company Shanghai Pharmaceuticals, which included distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities.

According to Pfizer, branded generics account for 60 per cent of the domestic market in China, with the country expected to become the world's second-largest pharmaceutical market by 2015.

Hua Bai, CEO and president of Hisun Pharmaceuticals, stated that such deals were the way forward for the company. He said: "Collaborating with the world's leading pharmaceutical companies to form potential joint ventures is a strategy being adopted by Hisun."

6th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics